Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule.
Cassidy
C A
CA
Eli Lilly and Company, Indianapolis, IN 46285, USA.
Peterson
P
P
Cirera
L
L
Roychowdhury
D F
DF
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D015897:Comorbidity; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D015994:Incidence; D017713:Platelet Transfusion; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D000093542:Gemcitabine
D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine